Alnylam Pharmaceuticals (ALNY) Q2 2025 10-Q Quarterly Report
Alnylam Pharmaceuticals (ALNY) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Jul 31, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Alnylam Pharmaceuticals Q2 2025 10-Q Analysis
Management Discussion & Analysis
- • Cash, cash equivalents, marketable securities sufficient for next 12 months from filing date
- • Potential need for significant additional funds earlier than expected
Alnylam Pharmaceuticals Q2 2025 Quarterly FinancialsXBRL
Revenue
$774M
▲ +17.3% YoY▲ +30.2% QoQ
Net Income
-$66M
▼ -292.4% YoY▼ -15.3% QoQ
Net Margin
-8.6%
▼ -601bp YoY▲ +111bp QoQ
Source: XBRL data from Alnylam Pharmaceuticals Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Alnylam Pharmaceuticals Quarterly Reports
Get deeper insights on Alnylam Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.